Active substanceSimethiconeSimethicone
Similar drugsTo uncover
  • Antiflat Lannacher
    suspension inwards 
    VALEANT, LLC     Russia
  • Antiflat Lannacher
    pills inwards 
    VALEANT, LLC     Russia
  • Bobotik®
    drops inwards 
  • Disflatil
    drops inwards 
  • Sub® simplex
    suspension inwards 
    Pfizer Inc.     USA
  • Espumizan®
    capsules inwards 
  • Espumizan® 40
    emulsion inwards 
    BERLIN-PHARMA, CJSC     Russia
  • Espumizan® L
    emulsion inwards 
    Berlin-Chemie, AG     Germany
  • Espumizan® baby
    drops inwards 
    Berlin-Chemie, AG     Germany
  • Espumizan® extra
    granules inwards 
    Berlin-Chemie, AG     Germany
  • Dosage form: & nbsporal suspension
    Composition:

    100 ml of the preparation contains:

    Active substance: simethicone 6.919 g (dimethicone 350: silicon dioxide, in the ratio of 92.5%: 7.5%)

    Excipients: hypromellose, carbomer, sodium citrate dihydrate, citric acid monohydrate, vanilla flavor, raspberry flavor, sodium cyclamate, sodium saccharinate, sodium benzoate, acid polyglycostearyl ethers, sorbic acid, water.

    Description:
    From white to gray-white color, slightly viscous suspension with a characteristic fruity smell (vanilla-raspberry).
    Pharmacotherapeutic group:Carminative
    ATX: & nbsp

    A.03.A.X   Other drugs used in bowel disorders

    Pharmacodynamics:

    Reducing the surface tension at the interface, complicates formation and contributes to the destruction of gas bubbles in intestinal contents. The gases released in this way can be absorbed by the walls of the intestine or removed by peristalsis. When sonogram and radiography prevents interference and overlapping images; promotes better irrigation of the mucous membrane of the colon with a contrast medium, preventing the rupture of the contrast film.

    Simethicone changes the surface tension of gas bubbles formed in the contents of the stomach and mucus of the intestine, and causes their destruction. The released gases are absorbed by the intestinal wall or removed during peristalsis of the intestine. Simethicone removes foam by physical means, does not enter into chemical reactions.

    Pharmacokinetics:

    Due to physical and chemical inertness is not absorbed in the body, after passing through the gastrointestinal tract is withdrawn in an unchanged form.

    Indications:

    - It is used as symptomatic therapy with increased gas formation, flatulence (including in the postoperative period);

    - preparation for diagnostic tests of the gastrointestinal tract (radiography, ultrasound, esophagogastroduodenoscopy);

    - acute poisoning with detergents containing surfactants, if they get into the stomach.

    Contraindications:
    Hypersensitivity to the active substance simethicone or to any of the auxiliary components of the drug, obstructive diseases of the gastrointestinal tract, intestinal obstruction.
    Pregnancy and lactation:
    Sab® Simplex can be used during pregnancy and lactation.
    Dosing and Administration:

    Inside.

    Increased gas formation

    Newborns and infants (up to 1 year of age) who are fed from a baby bottle: 15 drops (0.6 ml) of the suspension are added to each bottle.

    The Sab® Simplex mixes well with other liquids, such as milk.

    Children from one year to 6 years: 15 drops (0.6 ml) during or after a meal. If necessary, additionally 15 drops at night.

    Children from 6 to 15 years: 20 - 30 drops (0.8 - 1.2 ml).

    Adults: 30 - 45 drops (1.2 - 1.8 ml).

    This dose should be taken every 4 to 6 hours; If necessary, it can be increased.

    The Sab® Simplex is best taken during or after a meal and, if necessary, before going to bed.

    Sab® Simplex can be given to newborns before feeding from a teaspoon.

    Before use, shake the bottle vigorously. To start the suspension from the pipette, flip the bottle upside down and tap on the bottom. The duration of application depends on the dynamics of complaints. The Sab® Simplex can be taken for a long time if necessary.

    Preparation for diagnostic tests of the gastrointestinal tract

    Application in preparation for diagnostic studies of the gastrointestinal tract is facilitated if the pipette is removed from the vial.

    X-ray examination: to prepare for radiography on the day before the study in the evening should take 3-6 teaspoons (15-30 ml) of Sab® Simplex. Ultrasonography: when preparing for ultrasound it is recommended to take 3 teaspoons (15 ml) of Sab® Simplex the evening before the test and 3 teaspoons 3 hours before the test.

    Endoscopy: Before endoscopy, you should take 1/2 - 1 teaspoon (2.5 - 5 ml) of Sab® Simplex. During the examination, an additional several milliliters of suspensions of Sab® Simplex can be introduced through the endoscope.

    Poisoning with detergents

    The dose depends on the severity of the poisoning.The recommended minimum dose of Sab® Simplex is 1 teaspoon (5 ml).

    If you have any complaints and / or complaints, please contact your doctor.

    Side effects:

    Allergic reactions are possible.

    Overdose:

    Cases of drug overdose are not known.

    Interaction:

    Not installed.

    Special instructions:

    The drug Sab® Simplex can be used, including in patients with diabetes mellitus. does not contain carbohydrates.

    New and / or recurring complaints associated with increased gas production should be clinically confirmed.

    Effect on the ability to drive transp. cf. and fur:

    Does not affect the ability to drive and work with machinery.

    Form release / dosage:
    Suspension for oral administration 69,19 mg / ml.
    Packaging:

    To 30 ml in bottles of light-protective glass with a drop, device (25 drops in 1 ml). Each bottle along with the instruction is placed in a cardboard box.

    Storage conditions:
    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N014203 / 01
    Date of registration:21.05.2009 / 27.08.2010
    The owner of the registration certificate: Pfizer Inc. Pfizer Inc. USA
    Manufacturer: & nbsp
    Representation: & nbspPfizer H. Si. Pi. CorporationPfizer H. Si. Pi. Corporation
    Information update date: & nbsp23.06.2016
    Illustrated instructions
      Instructions
      Up